Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Phase II analysis ...

Compass Pathways stock reversed higher Tuesday on positive test results for its psychedelic drug in treatment-resistant depression.

Earlier in July 2026, COMPASS Pathways reported 26-week data from its second Phase 3 COMP006 trial of COMP360 psilocybin in ...

Compass has already submitted for approval of its psilocybin-based therapy to the FDA following previous Phase III success.

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc ...

Compass Pathways (CMPS) stock gains as Evercore ISI upgraded the company on the latest Phase 3 trial data for the company's ...

Compass Pathways plc upgraded to Strong Buy after phase 3 COMP360 TRD data & fast-track FDA NDA review; see catalysts, ...

Compass Pathways has announced six‑month results from its second phase 3 trial of COMP360, its synthetic formulation of ...

While about 100 clinical trials focused on psychedelic compounds are chugging along in the regulatory pathway to examine the potential the drugs have to treat illnesses like depression and alcoholism, ...